It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

In March 2022, she discovered that she had HER2 positive breast cancer ... has a higher than normal risk for another cancer or a recurrence." For patients just starting their cancer journey ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

The American Cancer Society is asking North Dakota State lawmakers to pass legislation that would require insurance companies to cover diagnostic testing for people who need it when doctors find ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...